AMRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
862.7M
+8.4%
796.2M
+10.2%
722.5M
-11.3%
814.3M
+3.8%
784.5M
Cost of Revenue
528.6M
+14.5%
461.7M
+14.7%
402.4M
-22.2%
517.1M
+1.3%
510.5M
Gross Profit
334.1M
-0.1%
334.5M
+4.5%
320.1M
+7.7%
297.2M
+8.5%
274.0M
Operating Expenses
238.7M
+16.6%
204.7M
+14.8%
178.3M
-6.3%
190.4M
-6.5%
203.6M
R&D
68.4M
+75.2%
39.0M
+1.7%
38.4M
+10.2%
34.8M
-45.0%
63.4M
SG&A
139.6M
-6.1%
148.7M
+7.1%
138.9M
-5.2%
146.5M
+6.3%
137.8M
Operating Income
95.4M
-26.5%
129.8M
-8.5%
141.8M
+32.8%
106.8M
+51.8%
70.3M
EBITDA
178.4M
-7.9%
193.8M
+1.2%
191.5M
+20.8%
158.5M
+27.2%
124.6M
Net Income
12.3M
-82.3%
69.6M
-10.8%
78.0M
+57.3%
49.6M
+173.4%
18.1M
EPS (Basic)
$-0.06
-133.3%
$0.18
-10.0%
$0.20
+81.8%
$0.11
+1000.0%
$0.01
EPS (Diluted)
$-0.06
-133.3%
$0.18
-5.3%
$0.19
+72.7%
$0.11
+1000.0%
$0.01
Shares (Diluted)
335.7M
+2.3%
328.1M
-0.3%
328.9M
+0.2%
328.1M
+1.0%
324.8M
Amneal Pharmaceuticals (AMRX) — Financials